A Bayesian Nonlinear Mixed-Effects Regression Model for the Characterization of Early Bactericidal Activity of Tuberculosis Drugs

Journal of Biopharmaceutical Statistics

Volumn 25, Issue 6, 2015, Pages 1247-1271

  Burger, Divan Aristo ^a,b   Schall, Robert ^a,b  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b IQVIA   (United States)

Author keywords

Bayesian nonlinear mixed effects (NLME) regression model; Biphasic; Colony forming unit (CFU) count; Early bactericidal activity (EBA)Tuberculosis (TB)

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; BAYES THEOREM; BAYESIAN NONLINEAR MIXED EFFECT; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT; EARLY BACTERICIDAL ACTIVITY; EMPIRICISM; HUMAN; LINEAR REGRESSION ANALYSIS; LINEAR SYSTEM; LOGLINEAR MODEL; MYCOBACTERIUM TUBERCULOSIS; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SLOPE FACTOR; TUBERCULOSIS; ALGORITHM; BACTERIAL COUNT; BACTERIAL LOAD; DRUG EFFECTS; LUNG TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NONLINEAR SYSTEM; PREDICTIVE VALUE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; BAYES THEOREM; COLONY COUNT, MICROBIAL; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MYCOBACTERIUM TUBERCULOSIS; NONLINEAR DYNAMICS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; TUBERCULOSIS, PULMONARY;

EID: 84944177336     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2014.971170     Document Type: Article

References (39)

1. Bacon, D. W., Watts, D. G. (1971). Estimating the transition between two intersecting straight lines. Biometrika 58:525-534.
2. Botha, F. J. H., Sirgel, F. A., Parkin, D. P., Van De Wal, B. W., Donald, P. R., Mitchison, D. A. (1996). Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. South African Medical Journal 86(2):155-158.
3. Brindle, R., Odhiambo, J. A., Mitchison, D. A. (2001). Serial counts for Mycobacterium tuberculosis in sputum as surrogate markers for the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulmonary Medicine 1(1):2.
4. Brooks, S. P., Gelman, A. (1998). General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 7:434-455.
5. Davies, G. R., Brindle, R., Khoo, S. H., Aarons, L. J. (2006a). Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrobial Agents and Chemotherapy 50:3154-3156.
6. Davies, G. R., Khoo, S. H., Aarons, L. J. (2006b). Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. Journal of Antimicrobial Chemotherapy 58:594-600.
7. Diacon, A. H., Dawson, R., Von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P. R., Conradie, A., Erondu, N., Ginsberg, A. M., Egizi, E., Winter, H., Becker, P., Mendel, C. M. (2013). Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 57(5):2199-2203.
8. Diacon, A. H., Dawson, R., Von Groote-Bidlingmaier, F., Symons, G. Venter, A., Donald, P. R., Van Niekerk, C., Everitt, D., Winter, H., Becker, P., Mendel, C. M., Spigelmin, M. K. (2012). 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomized trial. The Lancet 380:986-993.
9. Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H., Palaci, M., Johnson, J. L. (2008). Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 178:1180-1185.
10. Donald, P. R., Diacon, A. H. (2008). The early bactericidal activity of anti-tuberculosis drugs: A literature review. Tuberculosis 88(Suppl 1):S75-S83.
11. Geisser, S., Eddy, W. F. (1979). A predictive approach to model selection. Journal of the American Statistical Association 74:153-160.
12. Gelfand, A. E., Smith, A. F. M. (1990). Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association 85:398-409.
13. Gilks, W. R., Richardson, S., Spiegelhalter, D. J. (1996). Markov Chain Monte Carlo in Practice. London, UK: Chapman and Hall.
14. Gillespie, S. H., Gosling, R. D., Charalambous, B. M. (2002). A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. American Journal of Respiratory and Critical Care Medicine 166:31-35.
15. Griffiths, D. A., Miller, A. J. (1973). Hyperbolic regression-A model based on two-phase piecewise linear regression with a smooth transition between regimens. Communications in Statistics 2:561-569.
16. Grossman, M., Hartz, S. M., Koops, W. J. (1999). Persistency of lactation yield: A novel approach. Journal of Dairy Science 82(10):2192-2197.
17. Hahn, H., Bouvier, A., Kiu, K. (2013). R2Cuba: Multidimensional Numerical Integration. R package Version 1.0-11. URL: http://CRAN.R-project.org/package=R2Cuba
18. Jindani, A., Doré, C. J., Mitchison, D. A. (2003). Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. American Journal of Respiratory and Critical Care Medicine 167:1348-1354.
19. Kass, R. E., Natarajan, R. (2006). A default conjugate prior for variance components in generalized linear mixed models (comments on article by Browne and Draper). Bayesian Analysis 1 (3):535-542.
20. Kass, R. E., Raftery, A. E. (1995). Bayes factors. Journal of the American Statistical Association 90:773-795.
21. Lewis, S. M., Raftery, A. E. (1997). Estimating Bayes factor via posterior simulation with Laplace-Metropolis estimator. Journal of the American Statistical Association 92:648-655.
22. Lindley, D. V. (1993). On presentation of evidence. Mathematical Scientist 18:60-63.
23. Lunn, D. J., Spiegelhalter, D. J., Thomas, A., Best, N. G. (2009). The BUGS project: Evolution, critique and future directions. Statistics in Medicine 28:3049-3067.
24. Mitchison, D. A. (2006). Clinical development of anti-tuberculosis drugs. Journal of Antimicrobial Chemotherapy 58:494-495.
25. Mitchison, D. A., Davies, G. R. (2008). Assessment of the efficacy of new anti-tuberculosis drugs. The Open Infectious Diseases Journal 2:59-76.
26. Mitchison, D. A., Sturm, W. A. (1997). The measurement of early bactericidal activity, In Bailliere's Clinical Infectious Diseases: Mycobacterial Diseases Part II, Malin, A., McAdam, K. P. W. J. (eds.), 185-206. London: Bailliere Tindall.
27. Ntzoufras, I. (2009). Bayesian Modeling Using WinBUGS. Hoboken, New Jersey: John Wiley & Sons, Inc.
28. Phillips, P., Fielding, K. (2008). Surrogate markers for poor outcome to treatment for tuberculosis: Results from extensive multi-trial analysis. The International Journal of Tuberculosis and Lung Disease 12:S146-S147.
29. R Core Team. (2014). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria. URL: http://www.R-project.org/
30. Ratkowsky, D. A. (1983). Nonlinear Regression Modeling: A Unified Practical Approach. New York: Marcel Dekker.
31. Rustomjee, R., Lienhardt, C., Kanyok, T., Davies, G. R., Levin, J., Mthiyane, T., Reddy, C., Sturm, A. W., Sirgel, F. A., Allen, J., Coleman, D. J., Fourie, B., A., M. D., the Gatifloxacin for TB (OFLOTUB) Study Team (2008). A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease 12(2):128-138.
32. SAS Institute Inc. (2008). SAS/STATR 9.2 User's Guide. Cary, North Carolina: Author.
33. Seber, G. A. F., Wild, C. J. (1989). Nonlinear Regression. New York: Wiley Press.
34. Spiegelhalter, D. J., Best, N. G., Carlin, B. P., Van Der Linde, A. (2002). Bayesian measures of model complexity and fit (with discussion). Journal of the Royal Statistical Society 64:583-640.
35. Spiegelhalter, D. J., Thomas, A., Best, N. G., Lunn, D. (2003). Win-BUGS User Manual, Version 1.4. URL: http://www.politicalbubbles.org/bayes-beach/manual14.pdf.
36. O'Brien, R. J. (2002). Studies of the early bactericidal activity of new drugs for tuberculosis: A help or a hindrance to antituberculosis drug development?. American Journal of Respiratory and Critical Care Medicine 166:3-4.
37. Wallis, R. S., Doherty, T. M., Onyebujoh, P., Vahedi, M., Laang, H., Olesen, O., Parida, S., Zumla, A. (2009). Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet Infectious Diseases 9:162-172.
38. Ward, E. J. (2008). A review and comparison of four commonly used Bayesian and maximum likelihood model selection tools. Ecological Modelling 211:1-10.
39. Yang, Y., Li, X., Zhou, F., Jin, Q., Gao, L. (2011). Prevalence of drug-resistant tuberculosis in mainland china: Systematic review and meta-analysis. PLoS ONE 6(6):e20343. URL: http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020343.